Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Key Points
Key points are not available for this paper at this time.
Abstract
Nct01142726.
AI से पूछें
Like
Bookmark
Share
View Full Paper
AI से पूछें
Like
Bookmark
Share
View Full Paper
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period | Synapse